Trial Profile
An Open-Label Non-Interventional Evaluation of Efficacy of Symbicort Forte Turbuhaler 320/9 microg (Budesonide / Formoterol) and Symbicort Turbuhaler 160/4,5 microg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2011
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Feb 2009 New trial record